United States: Knowledge Of A Goal Does Not Render Its Achievement Obvious

In Institut Pasteur & Universite Pierre et Marie Curie v. Focarino, Nos. 12-1485, -1486, -1487 (Fed. Cir. Dec. 30, 2013), the Federal Circuit reversed the Board's decision that claims 10 and 12 of U.S. Patent No. 6,610,545 ("the '545 patent") were obvious; vacated and remanded the Board's decision that the claims of U.S. Patent No. 6,833,252 ("the '252 patent") were obvious; and dismissed as moot the Board's decision regarding U.S. Patent No. 7,309,605 ("the '605 patent").

Institut Pasteur and Universite Pierre et Marie Curie (collectively "Pasteur") own the '605, '545, and '252 patents, which claim methods and tools for inserting or deleting genes at targeted locations in the chromosomes of living cells ("gene targeting") using group I intron encoded endonucleases ("GIIE endonucleases").  Precision BioSciences, Inc. ("Precision") requested inter partes reexamination of each patent, and the examiner rejected a number of Pasteur's claims as obvious during reexamination.  The Board affirmed the examiner's rejections, and Pasteur appealed.  While the appeal was pending, the involved patents expired.

The Court dismissed as moot the appeal relating to the '605 patent, finding that Pasteur substantively narrowed the scope of claim 14 during reexamination by amending the claim to recite that the targeted DNA was "chromosomal."  The Court rejected Pasteur's argument that the scope was unchanged because the claim was already limited to chromosomal DNA.  Specifically, Pasteur argued that claim 14 was limited to "chromosomal DNA" even before the amendment because it recited that the targeted DNA undergoes homologous recombination with a newly introduced plasmid whose sequence is "homologous to the sequence of [a] chromosome."  Slip op. at 13 (alteration in original) (citation omitted).  The Court rejected this reasoning, finding that the newly introduced plasmid may be homologous to both chromosomal and nonchromosomal DNA, and, therefore, the original claim did not exclude homologous recombination in nonchromosomal DNA.  Therefore, the Court found that the amendment limiting the claims to chromosomal DNA changed the scope of the claims.  Because under 37 C.F.R. § 1.530(j) and (k), the PTO cannot issue an amended claim for an expired patent if the amendment substantively changes the claim's scope, the Court dismissed Pasteur's appeal relating to the '605 patent as moot.

The Federal Circuit next considered the Board's findings of obviousness with regard to claims 10 and 12 of the '545 patent.  The Court found that two of the cited references (Bell-Pedersen and Quirk) disclosed gene transfer into nonchromosomal DNA in prokaryotic cells, and agreed with the Board that the key issue was whether the relevant skilled artisan—after reading these two references—would have expected that a GIIE endonuclease would successfully promote targeted gene transfer into the chromosomal DNA of eukaryotic cells, and thus had good reason to pursue that possibility.  The Court held that the Board made prejudicial errors by making factual determinations about the prior art that were not supported by substantial evidence, and by failing to give proper consideration to at least two categories of evidence:  (1) teachings in the prior art that targeting a cell's chromosomal DNA could be toxic to the cell; and (2) industry praise and licensing of Pasteur's invention.

First, the Court found that the Board erred in finding that the Frey and Dujon references showed that a GIIE endonuclease cleaved yeast chromosomal DNA when expressed in yeast cells.  "Because no other references identified by the Board show a GIIE endonuclease cleaving chromosomal DNA in a eukaryotic cell, its errors were highly material to whether the '545 patent claims would have been obvious."  Id.  at 17.

"[T]he expectation-of-success analysis must match the highly desired goal, not switch to a different goal that may be a less challenging but also less worth-while pursuit."  Slip op. at 18 (citing KSR Int'l Co.v. Teleflex Inc., 550 U.S. 398, 421 (2007)).

The Court then found that the Board compounded its erroneous findings by ignoring teachings that targeting a GIIE endonuclease to chromosomal DNA in a living cell could be highly toxic.  The Court explained that the Board identified no reason at all that a skilled artisan would have pursued a method toxic to cells.  The Federal Circuit found that instead, the Board relied on the interest stated by the Old reference that "[i]t would be a great advance if such alterations could be engineered into copies of a chosen gene in situ within the chromosomes of a living animal cell."  Id. at 18 (alteration in original) (citation omitted).  The Court cautioned that "knowledge of the goal does not render its achievement obvious."  Id. (quoting Abbott Labs. v. Sandoz, Inc., 544 F.3d 1341, 1352 (Fed. Cir. 2008)).  The Court stated that "without a sound explanation for doing otherwise, which is not present here, the
expectation-of-success analysis must match the highly desired goal, not switch to a different goal that may be a less challenging but also less worth-while pursuit."  Id. (citing KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398, 421 (2007)).

Regarding objective indicia of nonobviousness, the Federal Circuit held that the Board erred by too finely parsing Pasteur's evidence of industry licensing and by dismissing Pasteur's evidence of praise based on a misreading of the prior art.  With regard to licensing, the Court explained that the Board rejected the evidence of licensing because the declaration by the inventor and exclusive licensee "did not establish that the third parties specifically licensed the patent family to gain access to the subject matter claimed in the '545 patent, rather than other technology described in the patent but not claimed or claimed in related patents."  Id. at 20 (citation omitted).  The Court found that theoretical possibility does not undermine the strong probative value of the licensing of the '545 patent, stating that "[t]he central success described in the patent is the one prior art hoped for and is captured in the claims at issue."  Id.

With regard to industry praise, the Court explained that while the Board acknowledged that Pasteur established a connection between the praise by the industry and the claimed homologous recombination step, the Board found that the step was possessed by the prior art and therefore not a proper basis to rebut the prima facie case of obviousness.  The Federal Circuit, however, found that under a correct reading of the Dujon reference, the step was not shown.  Thus, the Court held that industry praise, like others' licensing of Pasteur's invention, provided probative and cogent evidence that one of ordinary skill in the art would not have reasonably expected that a GIIE endonuclease could successfully modify chromosomal DNA in eukaryotic cells.  The Federal Circuit thus reversed the Board's rejection of claims 10 and 12 of the '545 patent.

Turning to the '252 patent, the Court noted that its disposition follows from its discussion of the '545 patent.  The '252 patent claims recite a recombinant mammalian chromosome comprising a GIIE endonuclease recognition site, which the Federal Circuit explained was a first step to practicing the method recited by claims 10 and 12 of the '545 patent.  In vacating the Board's conclusion and remanding to the Board for reconsideration, the Federal Circuit explained that the Board identified only a single reason that one of ordinary skill in the art would have attempted to make a recombinant chromosome containing a GIIE endonuclease recognition site:  to apply the homologous recombination method disclosed by the Bell-Pedersen and Quirk references to chromosomal DNA in mammalian cells.  The Court held that this reason was insufficient to support a determination of obviousness, for the reasons discussed in connection with the '545 patent.

The Federal Circuit explained that the Board never considered whether other motivations would have made the chromosome claimed by the '252 patent obvious.  Specifically, the Board did not make a finding about whether a skilled artisan would have introduced a GIIE endonuclease recognition site into a mammalian chromosome even without reasonably expecting its successful use for the site-directed insertion of DNA.  Although mentions were made at oral argument about other uses for such recombinant chromosomes, the Court cautioned that "obviousness is determined at the time the invention was made, so current uses for the recombinant chromosomes, without more, would not establish a sufficient motivation at the time of invention."  Id. at 24 (citation omitted).  Finally, regarding objective evidence of nonobviousness, the Court held that the use of the '252 patent claims as a necessary first step for a method that others in the industry licensed, praised, and copied, does not demonstrate that they did so because of that first step.  The Court thus vacated the Board's conclusion for the '252 patent and remanded for further consideration.

Judges:  Newman, Clevenger, Taranto (author)

[Appealed from Board]

This article previously appeared in Last Month at the Federal Circuit, January, 2014

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
27 Nov 2017, Seminar, London, UK

Finnegan partner Anthony Tridico will present “U.S. Patent Case Law Update” at the Chartered Institute of Patent Attorneys’ annual Patent Case Law Review.

28 Nov 2017, Seminar, Milan, Italy

Finnegan partner John Paul will present “Internet of Things: Patent Liability, Enforcement and Licensing” and will join the Mock WIPO Mediation at International Technology Transfer—Licensing and ADR, co-hosted by Licensing Executives Society and World Intellectual Property Organization.

29 Nov 2017, Seminar, Tel Aviv, Israel

Finnegan is a platinum sponsor IVC Research Center’s start-up forum, “The Most Promising Start Ups for 2017 – A Synergy of Big Data, Artificial Intelligence, Machine Vision and IoT.”

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.